Approval · Notice of Compliance 30097 · 2023
DIFLUCAN: Notice of Compliance 30097
Issued February 9, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30097
- Date
- February 9, 2023
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the product monograph with a drug-drug interaction with abrocitinib
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DIFLUCAN | Not yet assigned | — |
Medicinal ingredients
- FLUCONAZOLE 2 MG per ML
- FLUCONAZOLE 50 MG per TAB
- FLUCONAZOLE 100 MG per TAB
- FLUCONAZOLE 50 MG per 5ML